| OPERATING ROOM |
Healthios clients can access exclusive project material and proprietary content in a secure and consistent environment.
CLIENTS… log-in»
Welcome to Diagnostics!
From late breaking news to key company press releases, from financings to who is investing, you will find it here.
Sector Performance ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Companies |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investors |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calendar |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Executive Summary03.24.08
At $24.9 billion in revenues, the Diagnostics industry is projected to deliver another year of double-digit growth, following an 11% gain (in actual dollars) in 2003. Several factors contribute to its well-being, favorable currency exchange rates, continuing growth in molecular testing (NAT) and glucose monitoring (combined these account for 27% of industry sales), and worsening labor shortages that spur demand for lab automation and work-cell consolidation.... more»Leadership Review
PRO Medicus Ltd. announced the appointment of Mr Peter Kempen as a Non-Executive Director, effective March 12, 2008. Mr Kempen has more than 25 years experience working with many of Australia's leadin... more»
PRO Medicus Ltd. announced the appointment of Mr Peter Kempen as a Non-Executive Director, effective March 12, 2008. Mr Kempen has more than 25 years experience working with many of Australia's leadin... more»
Mergers & Acquisitions
Nicholas Piramal India (NPIL) is in discussions for the sale of a small stake in its research company, Piramal Life Sciences, top officials at the company said. “We will get additional funding w... more»
Nicholas Piramal India (NPIL) is in discussions for the sale of a small stake in its research company, Piramal Life Sciences, top officials at the company said. “We will get additional funding w... more»
Corporate Finance
SartoriusStedim Biotech and ProMetic Life Sciences Inc. announced the second successful technology transfer deal resulting from their collaboration entered into in 2006. The collaboration positions Sa... more»
SartoriusStedim Biotech and ProMetic Life Sciences Inc. announced the second successful technology transfer deal resulting from their collaboration entered into in 2006. The collaboration positions Sa... more»
News & Events
Exelixis Inc. announced that Genentech Inc. has exercised its option to further develop and commercialize Exelixis' compound XL518, a selective and potent inhibitor of MEK, which is currently in a pha... more»
Exelixis Inc. announced that Genentech Inc. has exercised its option to further develop and commercialize Exelixis' compound XL518, a selective and potent inhibitor of MEK, which is currently in a pha... more»
Earnings Announcements
Suven Life Sciences Ltd. reported earnings results for the quarter to December 2007. For the period, the company reported a 48% decrease in net profit at INR 20.1 million,sales decreased by 12% to INR... more»
Suven Life Sciences Ltd. reported earnings results for the quarter to December 2007. For the period, the company reported a 48% decrease in net profit at INR 20.1 million,sales decreased by 12% to INR... more»
Legal & Legislative
Dr. Reddy's Laboratories Ltd. entered into a settlement agreement with Novartis Pharma AG which involves a stipulation of dismissal of the lawsuits in the United States relating to the Abbreviated New... more»
Dr. Reddy's Laboratories Ltd. entered into a settlement agreement with Novartis Pharma AG which involves a stipulation of dismissal of the lawsuits in the United States relating to the Abbreviated New... more»
Strategic Development
Gambro AB announced the start of a strategic alliance with Sandoz, Inc. Both companies have agreed to cooperate in the launch of Sandoz' biosimilar Binocrit, the first biosimilar epoetin alfa which ha... more»
Gambro AB announced the start of a strategic alliance with Sandoz, Inc. Both companies have agreed to cooperate in the launch of Sandoz' biosimilar Binocrit, the first biosimilar epoetin alfa which ha... more»
